This new therapy turns off pain without opioids or addiction
Why it matters: This therapy could revolutionize chronic pain treatment, offering lasting relief without the opioid crisis's shadow.
- University of Pennsylvania School of Medicine scientists, in collaboration with Carnegie Mellon and Stanford, developed a gene therapy that directly targets pain-processing areas in the brain.
- The new therapy works by introducing a brain-specific "off switch" that reduces pain over a sustained period without affecting normal sensations or activating addiction-related reward pathways.
- AI-powered systems were used to map how pain is processed and to guide the design of this targeted gene therapy, ensuring it reproduces morphine's pain-relieving benefits without its dangers.
- Gregory Corder, PhD, co-senior author, highlights the goal of reducing pain while eliminating addiction risk, marking a significant step toward new relief for chronic pain sufferers.
Scientists have developed a groundbreaking gene therapy that acts as a precise "off switch" for chronic pain, mimicking morphine's benefits without its addictive risks or side effects. This innovative approach, detailed in a preclinical study published in Nature, leverages AI to target specific brain circuits, offering a potential new era of safer pain management for millions.
